Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

IXICO says it remains on target despite Alzheimer's study setback

The company is on track to meet market expectations, which means revenues are likely to grow by double digits
scientist at microscope
An unnamed client has stopped screening patients in the phase II/III study

IXICO Plc (LON:IXI) said an unnamed pharmaceutical client has stopped screening a phase II/III Alzheimer's Disease trial in which its specialist imaging services were being used.

Last September the US$7.7mln contract was extended to 2024. A total of US$2mln in payments have been recognised in the last two years.  

IXICO said the client's decision to stop the study was not related in anyway to its own performance.  

On track to meet expectations

It added that it remains on track to meet market expectations for the current financial year by generating double-digit revenue growth with turnover set to exceed of US$6mln (£4.5mln).

Investors were also told IXICO has a strong order book, a broad pipeline of opportunities and "commercial momentum which will support the continued growth of the business beyond the current financial year".

Chief executive Giulio Cerroni added: "We continue to provide our analytical services for subjects already enrolled on this clinical trial. We are also working closely with our client to plan patient follow up and data analysis activities as the study is closed down. 

"Whilst it is disappointing that this project will not continue for the full contract term, our broad neurological focus, order book and pipeline mitigates such challenges that can arise in our client's clinical development programmes."

 

View full IXI profile View Profile

IXICO Plc Timeline

Related Articles

surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
Picture of growing facility
May 07 2018
Establishing a vertically integrated business model provides THC with the ability to optimise efficiencies in the manufacturing process.
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use